Justia Patents Opinion Summaries

The 850 patent discloses a self-anchoring beverage container that prevents spills by anchoring the container to a surface. An International Trade Commission complaint, against several respondents (including Mayborn) alleged infringement of the patent and sought a general exclusion order (GEO) barring importation of infringing goods by any party. An ALJ determined that remaining respondents—those with whom the Complainants had not settled—were in default and infringed claim 1 of the patent. The defaulting respondents did not raise invalidity challenges. The ALJ recommended a GEO because it was difficult to gain information about entities selling the containers, and numerous entities were importing the containers, making it “nearly impossible to identify the sources.” The Commission issued the GEO in 2018. Mayborn took no action during the proceedings.In 2019, the Complainants notified Mayborn and its retail partners that Mayborn’s products infringed the patent in violation of the GEO. Mayborn petitioned the Commission to rescind its GEO under 19 U.S.C. 1337(k)(1), which allows the Commission to rescind or modify an order if “the conditions which led to such ... order no longer exist.” Mayborn argued that this requirement was satisfied because claim 1 of the patent was invalid under 35 U.S.C. 102, 103. The Federal Circuit affirmed the Commission’s denial of Mayborn’s petition. The asserted discovery of invalidating prior art after the issuance of a GEO is not a changed condition. View "Mayborn Group, Ltd. v. International Trade Commission" on Justia Law

Packet’s patents teach a method for monitoring packets exchanged over a computer network. A stream of packets between two computers is called a connection flow. Monitoring connection flows cannot account for disjointed sequences of the same flow in a network. The specifications explain that it is more useful to identify and classify “conversational flows,” defined as “the sequence of packets that are exchanged in any direction as a result of an activity.” Conversational flows provide application-specific views of network traffic and can be used to generate helpful analytics to understand network load and usage. The 789 patent recites apparatus claims’ the 725 and 751 patents recite method claims.Packet asserted claims against NetScout’s products under 35 U.S.C. 102. The jury found all claims willfully infringed, rejected NetScout’s invalidity defenses, and awarded pre-suit ($3.5 million) and post-suit ($2.25 million) damages. The court issued findings, rejecting NetScout’s section 101 invalidity defense, enhanced damages by $2.8 million, and awarded an ongoing royalty for post-verdict infringement. The Federal Circuit reversed in part and vacated the award of enhanced damages. The district court erred in denying NetScout’s motion for judgment as a matter of law on pre-suit damages. Packet is barred from recovering damages for pre-suit sales of the NetScout products because it failed to comply with the marking requirement. The court otherwise affirmed. View "Packet Intelligence LLC v. NetScout Systems, Inc." on Justia Law

Each patent at issue claims a method of treating cancer by administering antibodies targeting specific receptor-ligand interactions on T cells, which are responsible for processing information to develop an immune response in the body using receptors on their surfaces. The named inventor Dr. Honjo, a professor at Kyoto University, had shared information with Drs. Wood and Freeman until about 2001. In 2002, Honjo filed his patent application in Japan. Each patent at issue case claims priority from that patent application; none include Freeman and Wood as inventors.The Federal Circuit affirmed that Drs. Freeman and Wood should be deemed inventors of the subject matter of the patents alongside Dr. Honjo, 35 U.S.C. 116(a). The inventorship of a complex invention may depend on partial contributions to conception over time, and there is no principled reason to discount genuine contributions made by collaborators because portions of that work were published prior to conception for the benefit of the public. Earlier publication of an invention is obviously a potential hazard to patentability, but the publication of a portion of a complex invention does not necessarily defeat joint inventorship of that invention. View "Dana-Farber Cancer Institute v. Ono Pharmaceutical Co., Ltd." on Justia Law

Uniloc filed patent infringement actions against Apple, which moved to dismiss, arguing that Uniloc had granted its creditor a license with the right to sublicense in the event of a Uniloc default. According to Apple, Uniloc had defaulted and “lacked the right to exclude Apple from using the patents.” Apple’s motion referenced material that Uniloc had designated as highly confidential. Uniloc asked the court to seal most of the materials in the parties’ filings, including citations to case law, quotations from published opinions, and 23 entire exhibits, including matters of public record. The court denied that motion. Uniloc sought reconsideration, stating that it was willing to make public more than 90 percent of the material it had originally sought to shield; it submitted a declaration including individual grounds for redacting or sealing the remaining materials and declarations from third-party licensees that disclosure would cause them significant competitive harm. The court denied Uniloc’s motion.The Federal Circuit affirmed with respect to Uniloc’s requests to seal its purportedly confidential information and that of its related entities and vacated with respect to licensees. In denying Uniloc’s “sweeping motion,” the court sent a strong message that litigants should submit narrow, well-supported sealing requests and “took seriously the presumption of public access.” The court failed to make sufficient findings on balancing the public’s right of access against the interests of the third parties in shielding their financial and licensing information from public view. View "Uniloc 2017 LLC v. Apple, Inc." on Justia Law

Valencell’s patent, entitled “Methods and Apparatus for Generating Data Output Containing Physiological and Motion-Related Information,” concerns systems for monitoring information such as blood oxygen level, heart rate, and physical activity. Apple sought inter partes review (IPR) of claims 1–13. The Patent Board instituted review of several claims but denied review of claims 3–5. Fitbit then filed an IPR petition for claims 1, 2, and 6–13 and moved for joinder with Apple’s IPR. The Board granted Fitbit’s petition, terminating Fitbit’s separate proceeding. The Supreme Court then held that all patent claims challenged in an IPR petition must be reviewed by the Board if the petition is granted. The Board re-instituted conducted further proceedings and issued a Final Written Decision, finding claims 1, 2, and 6–13 unpatentable, and claims 3–5 not unpatentable. Following the decision, Apple withdrew from the proceeding. Valencell challenged Fitbit’s right to appeal as to claims 3–5.The Federal Circuit held that Fitbit has a right to appeal but vacated as to claims 3–5. Fitbit’s rights as a joined party apply to the entire proceedings and include the right of appeal, conforming to the statutory purpose of avoiding redundant actions by facilitating consolidation, while preserving statutory rights, including judicial review. The court remanded for review of the patentability of claims 3-5 in light of claims of obviousness. View "Fitbit, Inc. v. Valencell, Inc." on Justia Law

The Patent Trial and Appeal Board, in an ex parte appeal, affirmed an examiner’s rejection of claims in Boloro’s patent applications. Boloro moved to vacate. The Director of the Patent and Trademark Office acknowledged that the administrative patent judges (APJs) were not constitutionally appointed at the time of the Board’s final decision. The Federal Circuit has previously held that the appropriate remedy for such a constitutional violation was to vacate the Board’s decision and to remand for reassignment to a different panel of APJs for a new hearing and decision. The Director urges that the same remedy should not be extended to ex parte proceedings, like the Boloro proceedings, because the Director possesses “complete control over the initial examination” and could at any time before the Board proceedings have directed the issuance of Boloro’s patents but did not, consistent with the Board’s subsequent decisions. The Federal Circuit rejected that argument and remanded to the Board. View "In Re Boloro Global Ltd." on Justia Law

Genentech manufactures and sells bevacizumab, a biological product used to treat certain types of cancer, under the name Avastin. Amgen filed a biologics license application, 42 U.S.C. 262(k) to market a biosimilar version of Avastin—Mvasi. Mvasi received FDA approval effective September 2017. In October, Amgen notified Genentech of its intent to commercially market Mvasi starting no earlier than 180 days from the date of the letter. In August 2018, Amgen filed a third supplement to its Mvasi application to add a manufacturing facility and a fourth supplement to change its drug label. By July 2019, Amgen decided it would commercially launch Mvasi, intending to market it immediately. Genentech filed motions, seeking to preclude Amgen from commercially marketing Mvasi until Amgen “provides notice of its intent to commercially market such product” pursuant to 42 U.S.C. 262(l)(8) and 180 days have elapsed,” arguing that Amgen’s third and fourth supplements resulted in new and distinct applications that require new notices. The Federal Circuit affirmed the denial of the motions, reasoning that Amgen’s October 2017 commercial marketing notice for Mvasi satisfied Section 262(l)(8)(A)’s notice requirements. View "Genentech, Inc. v. Immunex Rhode Island Corp." on Justia Law

The patents at issue are directed to the fusion protein etanercept and methods of making the same. Etanercept is the active ingredient in Immunex’s biologic drug Enbrel®, which is primarily indicated for reducing the signs and symptoms of moderately to severely active rheumatoid arthritis, an autoimmune disorder. Sandoz filed an abbreviated Biologics License Application (aBLA), seeking approval to market Erelzi, a biosimilar version of Enbrel®. In a patent infringement suit under the Biologics Price Competition and Innovation Act, Sandoz stipulated to infringement of the asserted claims of the patents-in-suit. The district court held that Sandoz had failed to prove that the asserted claims of the patents-in-suit were invalid. The Federal Circuit affirmed, rejecting claims of obviousness-type double patenting; failure to meet the written description requirement; and obviousness. View "Immunex Corp v. Sandoz Inc." on Justia Law

ECT sued ShoppersChoice for infringement of its 261 patent, directed “to systems and methods that notify a party of travel status associated with one or more mobile things. ShoppersChoice challenged claim 11 as patent-ineligible, 35 U.S.C. 101. ShoppersChoice moved to join a patent eligibility hearing set in a parallel lawsuit, in which ECT alleged claim 11 infringement against other companies. The court conducted a consolidated hearing and invalidated claim 11 as directed to the abstract idea of providing advance notification of the pickup or delivery of a mobile thing. The Federal Circuit affirmed, holding that “the claim only entails applying longstanding commercial practices using generic computer components and technology.” ShoppersChoice sought attorney fees, citing evidence that ECT sent standardized demand letters and filed repeat infringement actions to obtain low-value “license fees” and force settlements. Before the court ruled, a California District Court awarded attorney fees against ECT in another case related to the patent.The Federal Circuit vacated a holding that the case was not exceptional. A pattern of litigation abuses characterized by the repeated filing of patent infringement actions for the sole purpose of forcing settlements, with no intention of testing the merits of one’s claims, is relevant to a district court’s exceptional case determination. The court clearly erred by failing to consider the objective unreasonableness of ECT’s alleging infringement of claim 11 against ShoppersChoice. View "Electronic Communication Technologies, LLC v. ShoppersChoice.Com, LLC" on Justia Law

On inter partes review (IPR) of B/E’s patents, the Patent Trial and Appeal Board found certain claims unpatentable as obvious. The patents relate to space-saving technologies for aircraft enclosures such as lavatory enclosures, closets, and galleys. The patents are directed to space-saving modifications to the walls of aircraft enclosures; they are not directed to the structures contained within those walls. The Federal Circuit affirmed, rejecting an argument that the Board incorporated a claim limitation that is not present in the prior art. The challenged claims would have been obvious because modifying a combination of prior art to include a second recess was nothing more than the predictable application of known technology. The Board fully articulated its conclusion of obviousness, and substantial evidence supports the Board’s determination of obviousness independent of whether it erred in considering design drawings. View "B/E Aerospace, Inc. v. C&D Zodiac, Inc" on Justia Law